ADVERTISEMENT In an effort to fulfil its 100-day pledge, the Commission is rushing to present the Act on 11 March in Strasbourg, but this has raised concerns among European pharma companies, who claim the process has bypassed proper evaluation. The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), representing small and medium-sized pharmaceutical companies, urged the Commission "to reconsider the haste with which the act is to be drafted, in a reply to a Commission call for